TECH Stock Recent News
TECH LATEST HEADLINES
Bio-Techne on Wednesday beat third-quarter profit and revenue estimates, helped by better-than-expected demand for its cell and gene therapy products and testing and diagnostic devices.
Last year was a tough one for biotech stocks. The Securities and Exchange Commission reported 41 bankruptcies following the Fed's interest rate hiking cycle, making it difficult to finance debt.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of GSK (GSK) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Why do you want to consider biotech stocks? Simply, the narrative comes down to numbers and a possible rotation.
MINNEAPOLIS, March 12, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Will Geist, President, Protein Sciences Segment, will present at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 19, 2024, at 9:45 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
MINNEAPOLIS , March 6, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024, at 8:30 a.m. EDT. A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Techne (TECH). But which of these two stocks is more attractive to value investors?
Although the revenue and EPS for Techne (TECH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Techne (TECH) came out with quarterly earnings of $0.40 per share, missing the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.47 per share a year ago.
Stocks in the biotech sector are always going to have massive potential. Health is arguably the most important aspect of life.